Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 3/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2790731 | 1.00 | AOC3 (0.64) | AOC3LTA4HKCNA3CHRNB2CHRNB4 | |
| SCHEMBL127394 | 1.00 | AOC3 (0.64) | AOC3LTA4HKCNA3CHRNB2CHRNB4 | |
| Water SCHEMBL28272635 | 0.98 | AOC3 (0.62) | AOC3LTA4HKCNA3CHRNB2CHRNB4 | |
| Ammonia Solution, Strong SCHEMBL27644989 | 0.98 | AOC3 (0.62) | AOC3LTA4HKCNA3CHRNB2CHRNB4 | |
| Phosphonic Acid SCHEMBL27635159 | 0.89 | AOC3 (0.53) | AOC3LTA4HKCNA3LMNAALDH1A1 | |
| SCHEMBL419306 | 0.89 | AOC3 (0.78) | AOC3LTA4HKCNA3HTR1BLMNA | |
| SCHEMBL419305 | 0.89 | AOC3 (0.78) | AOC3LTA4HKCNA3HTR1BLMNA | |
| Sulfuric Acid SCHEMBL28145485 | 0.88 | AOC3 (0.51) | AOC3LTA4HKCNA3CHRNB2CHRNB4 | |
| Phosphoric Acid SCHEMBL27513355 | 0.88 | AOC3 (0.51) | AOC3LTA4HKCNA3HTR1BRECQL | |
| Sulfuric Acid SCHEMBL28135054 | 0.88 | AOC3 (0.51) | AOC3LTA4HLMNAALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180015170-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC (US) | 2018-01-18 | — | — | US | disclosed |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130261173-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2013116200-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20130196946-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120225825-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-09-29 | — | — | US | disclosed |
| US-5004568-A | Reacting With Carbon Monoxide Using A Group 8 Noble Metal Halide Catalyst And A Group 1B Metal Halide | NATIONAL DISTILLERS AND CHEMICAL CORPORATION (US) | 1991-04-02 | — | — | US | disclosed |
| US-4767574-A | CATALYTIC WITH GROUP 8 NOBLE METAL HALIDE AND HALIDE COMPOUND | NATIONAL DISTILLERS AND CHEMICAL CORPORATION (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0217407-A2 | Carbonylation of allylic ethers to esters | QUANTUM CHEMICAL CORPORATION (a Virginia corp.) (US) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | AOC3 3928/4885LTA4H 4701/4885KCNA3 4837/4885 |
| US-20120225825-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | AOC3 3928/4885LTA4H 4701/4885KCNA3 4837/4885 |
| US-20130196946-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | AOC3 3928/4885LTA4H 4701/4885KCNA3 4837/4885 |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | AOC3 3928/4885LTA4H 4701/4885KCNA3 4837/4885 |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | AOC3 1067/4885LTA4H 632/4885KCNA3 4641/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | AOC3 1067/4885LTA4H 632/4885KCNA3 4641/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | AOC3 4157/4885LTA4H 2064/4885KCNA3 4064/4885 |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | AOC3 1067/4885LTA4H 632/4885KCNA3 4641/4885 |
| US-20130261173-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | AOC3 3928/4885LTA4H 4701/4885KCNA3 4837/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | AOC3 4157/4885LTA4H 2064/4885KCNA3 4064/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | AOC3 2698/4885LTA4H 2717/4885KCNA3 4280/4885 |
| US-20180015170-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | AOC3 3928/4885LTA4H 4701/4885KCNA3 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.